KR20170092975A - A composition for improving, preventing and treating of fatty liver diseases comprising porphyra tenera extract - Google Patents

Abstract

The present invention relates to a composition for treating, preventing, or ameliorating fatty liver diseases. By containing a laver (Porphyra tenera) extract as an active ingredient, it is possible to treat, prevent, or ameliorate non-alcoholic fatty liver diseases. In addition, the composition can be taken as foods since the composition is not toxic.

Description

[0001] The present invention relates to a composition for improving, preventing or treating fatty liver disease containing an extract of Kimchi,

The present invention is based on the finding that Porphyra tenera ) as an active ingredient to thereby improve, prevent or treat non-alcohol dependent fatty liver disease.

Most of the fat accumulated in the liver is triglyceride. The fatty liver is mainly caused by alcoholic fatty liver disease and nonalcoholic fatty liver disease (obesity, diabetes, hyperlipidemia, drug) , NAFLD).

Alcoholic fatty liver disease progresses from simple liver fatty liver to fatty liver and cirrhosis. Nonalcoholic fatty liver disease has been known to remain in simple fatty liver and does not progress. However, recently, it has been found that nonalcoholic fatty liver disease sometimes progresses from simple fatty liver to fatty liver or liver cirrhosis.

Recently, as the nutritional status improves and the adult diseases increase, the number of patients with fatty liver is increasing. According to the Korean Hepatology Society, the prevalence of liver disease has declined over the past decade, but the prevalence of fatty liver has tripled over 20 years, with the proportion of nonalcoholic fatty liver exceeding 50%, showing a rapid increase in the ratio of nonalcoholic fatty liver.

Nonalcoholic fatty liver disease is a disease characterized by fatty changes (steatosis) and lobular hepatitis (steatohepatitis), which are hallmarks of alcoholic hepatitis in liver biopsy, despite the absence of alcohol- . The pathologic findings of the liver are diverse, ranging from non-alcoholic Fatty Liver (NAFL) to non-alcoholic steatohepatits (NASH), fibrosis associated with hepatitis, and liver cirrhosis. Nonalcoholic fatty liver disease Is used to mean including.

Most of these nonalcoholic fatty liver diseases are accompanied by complications such as insulin resistance, obesity, diabetes, and hyperlipemia. In the presence of such complications, treatment should be performed. The principle of treatment for nonalcoholic fatty liver disease is improvement of lifestyle such as diet and exercise therapy, but it is a reality that it is difficult to carry out clearly. In particular, nonalcoholic fatty liver disease is more likely to progress to cirrhosis or hepatocellular carcinoma, so more active medication is needed.

To date, polyene phosphatidylcholine has been used clinically as a therapeutic agent for fatty liver. Fibrate-based drugs, such as clofibrate, a therapeutic agent for hyperlipidemia, have been used clinically in the treatment of fatty liver. The double fibrate drug is thought to improve lipid metabolism through liver oxidase enzyme in liver. However, the above-mentioned fibrate drugs have a side effect such as liver dysfunction.

Therefore, it is necessary to develop a therapeutic agent for the prevention and treatment of a new nonalcoholic fatty liver disease which has no side effects and excellent therapeutic effect.

Korean Patent No. 0899645 Korean Patent No. 0844366

An object of the present invention is steam (Porphyra tenera ) as an active ingredient. The present invention also provides a food composition for improving or preventing fatty liver disease.

It is another object of the present invention Kim (Porphyra tenera ) as an active ingredient. The present invention also provides a pharmaceutical composition for preventing or treating fatty liver disease.

To achieve the above object, the present invention provides a food composition for improving or preventing fatty liver disease, which comprises Porphyra tenera extract as an active ingredient.

The Porphyra tenera ) extract may be extracted with water, a lower alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof.

The mixed solvent may be 20 to 80% by volume of methanol, ethanol, butanol or propanol aqueous solution, preferably 20 to 80% by volume of ethanol aqueous solution.

The fatty liver disease may be a non-alcohol dependent fatty liver disease.

Also, prevention or pharmaceutical composition for the treatment of fatty liver of the present invention to achieve another object above diseases Kim (Porphyra tenera ) extract as an active ingredient.

The Porphyra tenera ) extract may be extracted with an ethanol aqueous solution of 20 to 80% by volume.

The fatty liver disease may be a non-alcohol dependent fatty liver disease.

The composition for improving, preventing or treating fatty liver disease of the present invention can alleviate the pathological findings due to non-alcoholic fatty liver such as fat accumulation and modification of liver tissue due to lipid accumulation, and thus the composition for preventing or treating non-alcoholic fatty liver disease It is effective.

In addition, the present invention can be used for a long term in non-alcoholic fatty liver disease because it has no side effects and is inexpensive because it contains the extract of Kim, which is a natural substance, as an effective ingredient.

FIG. 1 is a photograph of the fat accumulated in HepG2 cells of a group treated with the extract prepared according to Example 1 (OA + Example 1) in the control group, the OA group and the OA group by a red visible-light microscope.
FIG. 2 is a graph of absorbance measured after dissolving the stained control group, OA group and OA + Example 1 HepG2 cells in FIG.

The present invention is based on the finding that Porphyra tenera ) as an active ingredient to thereby improve, prevent or treat non-alcohol dependent fatty liver disease.

Hereinafter, the present invention will be described in detail.

The composition for improving, preventing or treating fatty liver disease of the present invention contains Porphyra tenera extract as an active ingredient.

The Porphyra tenera ) is a red and purplish red and purple flora. Its body is long, round, purple, and male. It is used as a food and medicine.

The Porphyra tenera ) is mixed with an extraction solvent at a weight ratio of 1: 5 to 25, preferably 1: 8 to 15, and extracted at 20 to 40 占 폚 to prepare an extract. The Porphyra If the weight ratio of tenera) and extraction solvent is outside the above range, Kim (Porphyra extract tenera ) can be extracted in a small amount. If the extraction temperature is lower than the lower limit value, the effective ingredient of steaming may not be extracted. If the extraction temperature is higher than the upper limit value, the effective ingredient of steaming may be extracted in a smaller amount.

The Porphyra tenera extract may be water, a lower alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof so as to be preferably used for the improvement, prevention or treatment of fatty liver disease. The mixed solvent is not particularly limited, but an extract obtained by extracting with 20 to 80% by volume of an aqueous solution of methanol, ethanol, butanol or propanol, more preferably 60 to 80% by volume of ethanol is preferable.

Herein Kim (Porphyra tenera) the term "extract" is used with reference, as well as crude extracts obtained by processing the extraction solvent Kim (Porphyra tenera ) extracts. For example, Porphyra tenera extract can be prepared in powder form by further processes such as vacuum distillation and lyophilization or spray drying.

In addition, the present invention ( Porphyra tenera ) extracts were broadly classified as Porphyra 0.0 > Porphyra < / RTI > tenera ) workpieces, such as Kim ( Porphyra tenera ) powder. Although in the present invention Kim ( Porphyra tenera ) extract, but it was found that Porphyra It will be appreciated by those skilled in the art that the desired effect can also be achieved in the form of a tenera workpiece.

On the other hand, "containing as the active ingredient" in this specification is the term Kim (Porphyra quot; enriched " or " tenera " ) extract. For example, the Porphyra tenera ) extract is used at a concentration of 10 to 1500 占 퐂 / ml, preferably 100 to 1000 占 퐂 / ml. Porphyra tenera ) extract is a natural product and does not have adverse effects on the human body even when it is administered in an excessive amount. Therefore, the extract of Porphyra The quantitative upper limit of the tenera extract can be selected by a person skilled in the art within a suitable range.

The pharmaceutical composition of the present invention can be prepared by using pharmaceutically acceptable and physiologically acceptable adjuvants in addition to the above-mentioned active ingredients. Examples of the adjuvants include excipients, disintegrants, sweeteners, binders, coating agents, swelling agents, lubricants, A lubricant or a flavoring agent can be used.

The pharmaceutical composition may be formulated into a pharmaceutical composition containing at least one pharmaceutically acceptable carrier in addition to the above-described active ingredients for administration.

The pharmaceutical composition may be in the form of granules, powders, tablets, coated tablets, capsules, suppositories, liquids, syrups, juices, suspensions, emulsions, drops or injectable solutions. For example, for formulation into tablets or capsules, the active ingredient may be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water, and the like. Also, if desired or necessary, suitable binders, lubricants, disintegrants and coloring agents may also be included as a mixture. Suitable binders include, but are not limited to, natural sugars such as starch, gelatin, glucose or beta-lactose, natural and synthetic gums such as corn sweeteners, acacia, tracker candles or sodium oleate, sodium stearate, magnesium stearate, sodium Benzoate, sodium acetate, sodium chloride, and the like. Disintegrants include, but are not limited to, starch, methyl cellulose, agar, bentonite, xanthan gum and the like.

Acceptable pharmaceutical carriers for compositions that are formulated into a liquid solution include sterile water and sterile water suitable for the living body such as saline, sterile water, Ringer's solution, buffered saline, albumin injection solution, dextrose solution, maltodextrin solution, glycerol, One or more of these components may be mixed and used. If necessary, other conventional additives such as an antioxidant, a buffer, and a bacteriostatic agent may be added. In addition, diluents, dispersants, surfactants, binders, and lubricants may be additionally added to formulate into injectable solutions, pills, capsules, granules or tablets such as aqueous solutions, suspensions, emulsions and the like.

Further, it can be suitably formulated according to each disease or ingredient, using the method disclosed in Remington's Pharmaceutical Science, Mack Publishing Company, Easton PA as an appropriate method in the field.

The pharmaceutical composition of the present invention can be administered orally or parenterally. In the case of parenteral administration, the composition can be administered by intravenous injection, subcutaneous injection, muscle injection, intraperitoneal injection, transdermal administration, etc., .

The appropriate dosage of the pharmaceutical composition of the present invention varies depending on factors such as the formulation method, administration method, age, body weight, sex, pathological condition, food, administration time, administration route, excretion rate and responsiveness of the patient, Usually, a skilled physician can readily determine and prescribe dosages effective for the desired treatment or prophylaxis. According to a preferred embodiment of the present invention, the daily dosage of the pharmaceutical composition of the present invention is 0.001-10 g / kg.

The pharmaceutical composition of the present invention can be prepared in unit dose form by formulating it with a pharmaceutically acceptable carrier and / or excipient or can be manufactured by inserting it into a multi-dose container. The formulations may be in the form of solutions, suspensions or emulsions in oils or aqueous media, or in the form of excipients, powders, granules, tablets or capsules, and may additionally contain dispersing or stabilizing agents.

The invention also Kim (Porphyra tenera ) as an active ingredient. The present invention also provides a food composition for improving, preventing or treating fatty liver disease.

The food composition according to the present invention can be formulated in the same manner as the above pharmaceutical composition and used as a functional food or added to various foods. Foods to which the composition of the present invention can be added include, for example, beverages, alcoholic beverages, confectioneries, diet bars, dairy products, meat, chocolates, pizza, ram noodles, other noodles, gums, ice cream, .

The food composition of the present invention contains, as an active ingredient, Porphyra tenera ) extract, as well as components commonly added in the manufacture of foodstuffs, including, for example, proteins, carbohydrates, fats, nutrients, flavoring agents and flavoring agents. Examples of the above-mentioned carbohydrates are monosaccharides such as glucose, fructose, and the like; Disaccharides such as maltose, sucrose, oligosaccharides and the like; And polysaccharides such as dextrin, cyclodextrin and the like, and sugar alcohols such as xylitol, sorbitol and erythritol. Natural flavorings such as tau martin and stevia extract (e.g., rebaudioside A and glycyrrhizin) and synthetic flavorings (saccharine, aspartame, etc.) can be used as flavorings. For example, when the food composition of the present invention is made of drinks and beverages, the steam (Porphyra of the invention tenera extract, citric acid, liquid fructose, sugar, glucose, acetic acid, malic acid, fruit juice, and various plant extracts.

The present invention is the steam (Porphyra tenera ) as an active ingredient. The present invention also provides a health functional food comprising a food composition for improving, preventing or treating fatty liver disease. Health functional food means Kim ( Porphyra tenera extract is added to a food material such as beverage, tea, spice, gum, confectionery, or the like, which is prepared by encapsulation, powdering, suspension or the like, Unlike medicines, there is an advantage that there are no side effects that can occur when a food is used as a raw material for a long time. The health functional food of the present invention thus obtained is very useful because it can be ingested routinely. In such health functional foods, Porphyra tenera) to the amount of the extract, and can not be absolutely specified depending on the type of functional food subject, and the addition in a range that does not impair the food original taste, usually 0.01 to 50% by weight with respect to the target food, preferably Is in the range of 0.1 to 20% by weight. In the case of health functional foods in the form of pills, granules, tablets or capsules, they may be added usually in the range of 0.1 to 100% by weight, preferably 0.5 to 80% by weight. In one embodiment, the health functional food of the present invention may be in the form of a pill, tablet, capsule or beverage.

The invention also Kim (Porphyra for the manufacture of a medicament or food for improving the fatty liver disease, preventing or treating tenera ) extract. As described above, Kim ( Porphyra tenera ) extract can be used for the purpose of improving, preventing or treating fatty liver disease.

The invention also Kim (Porphyra an effective amount to a mammal tenera < / RTI > extract of the present invention.

The term "mammal " as used herein refers to a mammal that is the subject of treatment, observation or experimentation, preferably a human.

As used herein, the term "effective amount" refers to the amount of active ingredient or pharmaceutical composition that elicits a biological or medical response in a tissue system, animal, or human, as contemplated by a researcher, veterinarian, physician or other clinician, ≪ / RTI > inducing a reduction of the symptoms of the disease or disorder. The effective amount and the administration frequency for the active ingredient of the present invention can be changed according to the desired effect. Thus, the optimal dosage to be administered can be readily determined by those skilled in the art and will vary with the nature of the disease, the severity of the disease, the amount of active and other ingredients contained in the composition, the type of formulation, and the age, The age, body weight, sex, diet, time of administration, route of administration and fraction of the composition, duration of treatment, concurrent medication, and the like. A method for preventing, treating or improving of the present invention, in the case of adults, Kim (Porphyra tenera ) extract is preferably administered at a dose of 0.001 g / kg to 10 g / kg once or several times a day.

In the treatment method of the present invention Kim (Porphyra tenera extract as an active ingredient can be administered in a conventional manner via oral, rectal, intravenous, intraarterial, intraperitoneal, intramuscular, intrasternal, percutaneous, topical, intraocular, or intradermal routes.

It will be apparent to those skilled in the art that various modifications and variations can be made in the present invention without departing from the spirit or scope of the present invention. Such variations and modifications are intended to be within the scope of the appended claims.

Example 1. Extraction with 70 vol% ethanol aqueous solution

The steam obtained from Daechun 70% by volume aqueous ethanol solution in a 1: After a mixture in a weight ratio of 10 extracted at 25 ℃ for 24 hours, then centrifuged for 30 min 8000xg to remove the precipitate and obtain the supernatant only Kim (Porphyra tenera ) extract was prepared.

Example 2. 20 vol% ethanol extraction

The procedure of Example 1 was repeated except that 20 vol% ethanol aqueous solution was used as an extraction solvent.

Example 3. Water Extraction

The procedure of Example 1 was repeated except that water was used as the extraction solvent.

Example 4. 70% by volume methanol extraction

The procedure of Example 1 was repeated except that 70 vol% methanol aqueous solution was used as an extraction solvent.

Example 5. 70% by volume hexane extraction

The procedure of Example 1 was repeated except that 70 vol% methanol aqueous solution was used as an extraction solvent.

<Test Example>

HepG2 cells were purchased from the American Type Culture Collection (ATCC, Manassas, Va., USA) and DMEM (Dulbeccos Modified Eagles Media) and bovine serum albumin (BSA) were purchased from Daegu (Korea).

An oil red O solution and MTT (3- (4,5-dimethylthiazol-2-yl) -2,5-diphenyltetrazolium bromide) were also purchased from Sigma-Aldrich (USA).

The term "oil red O staining" in the present invention refers to a kind of dyeing method in which oil fat O is used to stain intracellular fat red. The term "oil red O solution" in the present invention refers to a solution obtained by dissolving oil red O in a solvent such as isopropyl alcohol, ethanol, methanol, propylene glycol, etc., Preferably, the amount of isopropyl alcohol to be dissolved is varied depending on the kind of solvent and the condition of dyeing, but it is preferable to dissolve to the point where saturation is considered in consideration of economical efficiency while maximizing dyeing efficiency.

Test Example 1. Confirmation of fat accumulation inhibition _ Quantitative confirmation

FIG. 1 is a graph of absorbance measured after dissolving a control, OA group and OA + Example 1 HepG2 cells stained with an oil red O solution.

Specifically, the following tests were performed to quantitatively identify the intracellular accumulated fats of the control group, OA group, and OA + Example 1.

In the control group, HepG2 cells were inoculated on a 24-well cell culture plate and cultured in a low glucose DMEM medium supplemented with 1% BSA at 37 ° C and 5% CO ₂ for 24 hours, followed by incubation at room temperature (23-26 ° C) The cells were washed with phosphate buffered saline (PBS) three times and then incubated with 200 μL of 60% isopropanol for 5 minutes. Finally, the cells were incubated with 200 μL of 0.1% Oil Red O solution for 60 minutes at room temperature Lt; / RTI &gt;

OA group (induction group) was prepared by adding 0.5 mM oleic acid to low glucose DMEM medium supplemented with 1% BSA and then incubating HepG2 cells for 24 hours at 37 ° C and 5% CO _2, Lt; / RTI &gt;

In the treatment group (OA + Examples 1 to OA + Example 5), the OA group medium was treated with the 200 쨉 g / ml Kim extract prepared in Examples 1 to 5, and then HepG2 cells were cultured at 37 ° C in 5% CO ₂ for 24 hours and then stained in the same manner as the control.

 Cells of each group stained with the oil red O solution were dissolved in isopropanol for 10 minutes, and 100 μl of the dissolved solution was transferred to a 96-well plate and absorbance was measured at a wavelength of 510 nm.

As shown in FIG. 1, in the OA group, the accumulation amount of fat was increased by 60% as compared with the control group by oleic acid, but the OA group was treated with the Kim extracts of Examples 1 and 2 (OA + Example 1 and OA + 2), the fat accumulation was only 21% and 24% higher than the control group, respectively. This indicates that the kim extract obtained according to Examples 1 and 2 exhibits an excellent fat accumulation inhibitory effect, showing a fat accumulation inhibitory effect of about 34%.

On the other hand, in OA + Example 3 and OA + Example 4, the accumulation amount of fat was increased by 33% to 38% as compared with the control, and the accumulation amount of fat in OA + Example 5 was increased by 51% 5 did not show an excellent fat accumulation inhibitory effect as compared with Examples 1 and 2.

Test Example  2. Confirmation of fat accumulation _ Check photos

Of the cells of each group stained according to the method of Test Example 1, only the control group, OA group, and OA + cells of Example 1 were washed with 1 ml of water and identified by a red visible-light microscope (Olympus, Tokyo, Japan).

FIG. 2 is a photograph of the fat accumulated in HepG2 cells of the group treated with the extract prepared according to Example 1 (OA + Example 1) in the control group, the OA group and the OA group by a red visible-light microscope.

As shown in FIG. 2, it was confirmed that OA + Example 1 had significantly lower intracellular fat accumulation than OA group. These results indicate that the Kim extract prepared according to Example 1 of the present invention is excellent in the effect of inhibiting fat accumulation.

Test Example  3. Cytotoxicity check

OA group (derived group) is 24 hours under and then inoculated into HepG2 cells in 24-well plate was added to 0.5 mM oleic acid (oleic acid) in low-glucose DMEM medium supplemented with a 1% BSA was added 37 ℃, 5% CO ₂ conditions After incubation, 10 μl of 5 mg / ml MTT stock was added. After 3 hours, the medium was removed and the cells changed to purple. The cells were then dissolved in DMSO and transferred to a 96-well plate in an amount of 100 μl. The absorbance at 540 nm was measured to determine cytotoxicity Respectively.

The DMEM medium of the OA group was treated with the extract of 200 / / ml of Kim extract prepared in Examples 1 to 5, and cultured for 24 hours at 37 캜 in 5% CO _2. Then, 5 mg / Ml MTT stock, and after 3 hours, the medium was removed and the cells changed to purple. The cells were then dissolved in DMSO and transferred to a 96-well plate in an amount of 100 μl. The absorbance at 540 nm was measured to confirm cytotoxicity.

division OA OA + Example 1 OA + Example 2 OA + Example 3 OA + Example 4 OA + Example 5 Cell viability
(%) 100 95.1 92.6 93.8 92.4 93.3

As shown in Table 1 above, it was confirmed that the extract of Kim extract according to Examples 1 to 5 of the present invention showed no toxicity.

Test Example  4. LINE ( histone acetyltransferase ) Activity analysis

In order to confirm the possible inhibition of lipid accumulation by the inhibition of transcriptional activity of proteins involved in fat accumulation, the activity of HAT enzyme directly related to the control of transcription activity was observed in vitro by cell free method.

Specifically, HAT activity assays were performed using commercially available kits according to the manufacturer's protocol (Biovision Bio).

division Control group Example 1 Example 2 Example 3 Example 4 Example 5 Hela nuclear extract (占 퐂 / ml) 25 25 25 25 25 25 Extract content
(占 퐂 / ml) 0 200 200 200 200 200 HAT activity
(%) 100 80.1 90.3 98.2 95.6 93.9

As shown in FIG. 2, the extract of Example 1 contained the extract of Hela as a HAT enzyme source, and ascertained that HAT enzyme activity increased by the extract of Examples 1 to 5 to some extent. As a result, It was confirmed that the activity of about 20% was inhibited. On the other hand, the extracts of Examples 2 to 5 showed that the activity of about 6 to 9% was inhibited.

Accordingly, the Kim extract of Example 1 has excellent inhibitory effect on histone acetylation of various target genes involved in the increase of fat accumulation, thus indirectly suggesting the inhibition of transcriptional activity.

Hereinafter, formulation examples of the composition containing the powder of the present invention will be described, but the present invention is not intended to be limited thereto but is specifically described.

Preparation Example 1. Preparation of powder

500 mg of the extract powder obtained in Example 1

Lactose 100 mg

Talc 10 mg

The above components are mixed and filled in airtight bags to prepare powders.

Formulation Example 2. Preparation of tablets

300 mg of the extract powder obtained in Example 1

Corn starch 100 mg

Lactose 100 mg

Magnesium stearate 2 mg

After mixing the above components, tablets are prepared by tableting according to the usual preparation method of tablets.

Formulation Example 3. Preparation of capsules

200 mg of the extract powder obtained in Example 1

Crystalline cellulose 3 mg

Lactose 14.8 mg

Magnesium stearate 0.2 mg

The above components are mixed according to a conventional capsule preparation method and filled in gelatin capsules to prepare capsules.

Formulation example  4. Preparation of injections

600 mg of the extract powder obtained in Example 1

180 mg mannitol

Sterile sterilized water for injection 2974 mg

Na ₂ HPO _4, 12H ₂ O 26 mg

It is prepared by the above-mentioned component content per ampoule according to the usual injection preparation method.

Formulation Example 5. Preparation of a liquid preparation

4 g of the extract powder obtained in Example 1

10 g per isomer

5 g mannitol

Purified water quantity

Each component was added and dissolved in purified water according to the usual liquid preparation method, and the lemon flavor was added in an appropriate amount. Then, the above components were mixed, and purified water was added thereto. The whole was adjusted to 100 g with purified water, To prepare a liquid agent.

Preparation Example 6 Preparation of Granules

1,000 mg of the extract powder obtained in Example 1

Vitamin mixture quantity

70 [mu] g of vitamin A acetate

Vitamin E 1.0 mg

Vitamin B1 0.13 mg

0.15 mg of vitamin B2

Vitamin B6 0.5 mg

0.2 [mu] g vitamin B12

Vitamin C 10 mg

Biotin 10 μg

Nicotinic acid amide 1.7 mg

50 ㎍ of folic acid

Calcium pantothenate 0.5 mg

Mineral mixture quantity

1.75 mg of ferrous sulfate

0.82 mg of zinc oxide

Magnesium carbonate 25.3 mg

Potassium monophosphate 15 mg

Secondary calcium phosphate 55 mg

Potassium citrate 90 mg

Calcium carbonate 100 mg

Magnesium chloride 24.8 mg

The composition ratio of the above-mentioned vitamins and minerals is comparatively comparatively mixed with the granules according to the preferred embodiment. However, the blending ratio may be arbitrarily changed, and the above components are mixed according to the ordinary granule preparation method, Can be prepared and used in the manufacture of a health functional food composition according to a conventional method.

Formulation example  7. Manufacture of functional beverages

 1,000 mg of the extract powder obtained in Example 1

Citric acid 1,000 mg

100 g of oligosaccharide

Plum concentrate 2 g

Taurine 1 g

Purified water was added to the flask to obtain a total of 900 mL

The above components were mixed according to a conventional health drink manufacturing method, and the mixture was stirred and heated at 85 DEG C for about 1 hour. The solution thus prepared was filtered and sterilized in a sterilized 2 L container, It is used in the production of the functional beverage composition of the invention.

Although the composition ratio is a mixture of the components suitable for the preferred beverage as a preferred embodiment, the blending ratio may be arbitrarily varied according to the regional and national preferences such as the demand level, the demanding country, and the intended use.

Claims (8)

A food composition for improving or preventing fatty liver disease, which comprises an extract of Porphyra tenera as an active ingredient. The food composition according to claim 1, wherein the Porphyra tenera extract is extracted with water, a lower alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof. The food composition for improving or preventing fatty liver disease according to claim 1, wherein the mixed solvent is an aqueous solution of methanol, ethanol, butanol or propanol in an amount of 20 to 80% by volume. The food composition for improving or preventing fatty liver disease according to claim 1, wherein the mixed solvent is an ethanol aqueous solution of 20 to 80% by volume. The food composition for improving or preventing fatty liver disease according to claim 1, wherein the fatty liver disease is a non-alcohol dependent fatty liver disease. Porphyra tenera ) extract as an active ingredient. [Claim 7] The pharmaceutical composition according to claim 6, wherein the Porphyra tenera extract is extracted with 20 to 80% by volume aqueous ethanol solution. The pharmaceutical composition for preventing or treating fatty liver disease according to claim 6, wherein the fatty liver disease is a non-alcohol dependent fatty liver disease.

Images